相关实验视频

Updated: Jul 12, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

在质母细胞瘤微环境中的CD8+CD103+PD1+TIM3+T细胞与预后相关

Giulia Romagnoli¹, Quintino Giorgio D'Alessandris^2,3, Imerio Capone¹

¹Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

|October 26, 2023

概括

组织内存T细胞 (Trm) 上特定免疫检查点的低表达可能预测质母细胞瘤 (GB) 患者的更好的生存率. 识别这些Trm子集可以改善质母细胞瘤治疗策略.

科学领域:

神经瘤学神经瘤学
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

质母细胞瘤 (GB) 是一种高度侵略性的脑瘤,预后不好.
免疫检查点抑制剂 (ICI) 在GB的有效性有限,需要对瘤微环境 (TME) 进行更深入的了解.
组织内存T细胞 (Trm) 在抗瘤免疫中起着至关重要的作用.

研究的目的:

为了研究 GB 患者在 Trm 上免疫检查点表达的预后值.
为了将Trm表型与整体存活率 (OS) 和无进展生存率 (PFS) 相关联.

主要方法:

单一队列观察性研究45 GB患者.
多参数流细胞计分析Trm的表型.
单变量和多变量分析,以评估与生存结果的相关性.

主要成果:

减少表达Trim编程细胞死亡蛋白1 (PD1) 和T细胞免疫球蛋白和粘素域含蛋白3 (TIM3) 的频率与患者的生存率改善有关.
低CD8+CD103+PD1+TIM3+Trm和卡诺夫斯基绩效状态 (KPS) ≥70是较长寿命的独立预测因素.
CD8+CD103+Trm子集还显示了与年龄相关的生存预测值.

结论:

在Trm上的免疫检查点表达,特别是PD1和TIM3,可以作为GB的预后生物标志物.
识别Trm免疫检查点表达低的患者可以指导治疗策略.
对Trm介导免疫的进一步研究可能会提高质母细胞瘤治疗结果.

关键词:

这就是PD1 PD1.时间3 TIM3 年龄的年龄年龄的年龄.疾病的结果疾病的结果质母细胞瘤 (glioblastoma) 是一种预测者预测者预测者组织内存T细胞 (Trm)

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...